Skip to main content
main-content
Top

Expert commentary: DECLARE-TIMI 58

Miles Fisher talks to medwireNews about the results of the dapagliflozin cardiovascular outcomes trial DECLARE-TIMI 58.


More on this topic

Flash glucose monitoring technology

Browse new slide sets summarizing the latest results from real-world studies.

Image Credits